Starting treatment for chronic myeloid leukemia (CML) can be tough. Many people don't get their disease under control well enough, or they have side effects that make life difficult. The goal is to find a treatment that works well and is easy to live with for the long term. In a major trial, a new drug called asciminib was compared to the standard first-line treatments. After about two years, significantly more people taking asciminib achieved a deep level of disease control called a major molecular response, compared to those on the standard drugs. This was true whether asciminib was compared to all standard drugs together, or just to the older drug imatinib. The side effect profile also looked better. Fewer people on asciminib needed to reduce their dose or temporarily stop treatment compared to those on newer, 'second-generation' standard drugs. People were also less likely to have to stop asciminib completely because of side effects compared to those second-generation drugs. With this longer follow-up, asciminib continued to show a better balance of benefits and risks than the current standard treatments for newly diagnosed CML.
Asciminib superior to IS-TKIs in newly diagnosed CML-CP: MMR 74.1% vs 52.0% at 96 weeksCould a new leukemia drug work better and cause fewer side effects than current treatments?
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Consider asciminib as a frontline treatment option for newly diagnosed CML-CP based on superior efficacy and favorable tolerability versus IS-TKIs.
The ASC4FIRST trial is a phase 3 randomized trial comparing asciminib with investigator-selected tyrosine kinase inhibitors (IS-TKIs) in patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP). The primary analysis demonstrated superior efficacy for asciminib versus all IS-TKIs and versus imatinib in the imatinib stratum. A secondary analysis, with a median follow-up of 2.2 years, reported major molecular response (MMR) rates at week 96. The MMR rate was 74.1% with asciminib versus 52.0% with IS-TKIs (treatment difference, 22.4%; 95% confidence interval [CI], 13.6-31.3; 1-sided P<.001). In the imatinib stratum, the MMR rate was 76.2% with asciminib versus 47.1% with imatinib (treatment difference, 29.7%; 95% CI, 17.6-41.8; 1-sided P<.001). Compared to second-generation (2G) TKIs, the MMR rate was 72.0% with asciminib versus 56.9% with 2G TKIs (treatment difference, 15.1%; 95% CI, 2.3-28.0; 1-sided P<.05), suggesting possible clinical benefit, though the study was not designed to formally confirm statistical significance for this secondary endpoint. Regarding safety and tolerability, dose reductions occurred in 18.5% of patients on asciminib, 23.2% on imatinib, and 54.9% on 2G TKIs. Dose interruptions occurred in 46.5% on asciminib, 47.5% on imatinib, and 63.7% on 2G TKIs. The hazard ratio for time to discontinuation of treatment due to adverse events for asciminib versus 2G TKIs was 0.46 (95% CI, 0.215-0.997). With longer follow-up, asciminib continued to demonstrate a favorable benefit-risk profile over IS-TKIs and imatinib, supporting its potential as a treatment option for newly diagnosed CML-CP.
What this means for you:
A new drug for chronic myeloid leukemia showed better disease control and fewer treatment-disrupting side effects than current standard options. More on Acute Myeloid Leukemia
Case report on asciminib plus ponatinib or axitinib in CML relapse with B lymphoblastic blast crisis
New combo drug stops leukemia that fought back against two drugs
This case report describes a single CML patient who relapsed with B lymphoblastic blast crisis harboring a T315I mutation and a novel e6a3 B…
A new three-drug mix stops a tough leukemia that grew stronger after two drugs failed to control it.
AZA or LDAC combined with venetoclax likely improves mortality, remission, and quality of life
New combinations show promise for older adults with myeloid leukemia
This systematic review and meta-analysis of 47 studies evaluated treatments for older adults with AML ineligible for conventional chemothera…
Combining specific drugs like venetoclax with other treatments may improve survival and quality of life for older adults with acute myeloid …
7-day venetoclax with intensive chemotherapy achieves 90.3% composite complete remission in AML
Trial shows venetoclax combined with chemotherapy for AML
This clinical trial of 259 newly diagnosed patients with acute myeloid leukemia found a 90.3% composite complete remission rate using a 7-da…
A new clinical trial shows that a short 7-day course of venetoclax combined with chemotherapy can achieve high remission rates in AML patien…
Novel strategies aim to separate GVHD from GVL effects in allo-HCT for AML
Novel strategies aim to separate GVHD from GVL effects in leukemia patients
This narrative review explores novel therapeutic strategies to separate graft-versus-host disease (GVHD) from graft-versus-leukemia (GVL) ef…
A narrative review explores new ways to treat acute myeloid leukemia while managing side effects after stem cell transplants.
View Original Abstract ↓
Many patients receiving frontline tyrosine kinase inhibitors (TKIs) for chronic-phase chronic myeloid leukemia (CML-CP) experience inadequate disease control and/or adverse events (AEs) that impair quality of life. Treatments offering optimal efficacy, safety, and tolerability will support long-term therapy. In the primary analysis from the ASC4FIRST trial, a phase 3 randomized trial comparing asciminib with investigator-selected TKIs (IS-TKIs) in newly diagnosed CML-CP, asciminib demonstrated superior efficacy vs all IS-TKIs and vs imatinib in the imatinib stratum, meeting both primary objectives. In the secondary analysis (2.2 years' median follow-up), major molecular response (MMR) rate at week 96 was 74.1% with asciminib vs 52.0% with IS-TKIs (treatment difference, 22.4% [95% confidence interval (CI), 13.6-31.3]; 1-sided P< .001) and 76.2% with asciminib vs 47.1% with imatinib in the imatinib stratum (treatment difference, 29.7% [95% CI, 17.6-41.8]; 1-sided P< .001), meeting both key secondary objectives. MMR rate was 72.0% with asciminib vs 56.9% with second-generation (2G) TKIs (treatment difference, 15.1% [95% CI, 2.3-28.0]; 1-sided P< .05), suggesting possible clinical benefit, although the study was not designed to formally confirm statistical significance for this secondary end point. Safety/tolerability remained favorable with asciminib vs IS-TKIs. Dose reductions and interruptions, respectively, occurred with asciminib (18.5%; 46.5%), imatinib (23.2%; 47.5%), and 2G TKIs (54.9%; 63.7%). The hazard ratio for time to discontinuation of treatment due to AEs for asciminib vs 2G TKIs was 0.46 (95% CI, 0.215-0.997). With longer follow-up, asciminib continued to demonstrate a favorable benefit-risk profile over IS-TKIs and imatinib, supporting its potential as a treatment option for newly diagnosed CML-CP. This trial was registered at www.clinicaltrials.gov as NCT04971226.
Experimental agents show response rates up to 70% in relapsed or refractory diffuse large B-cell lymphoma
New cancer therapies double response rates for tough lymphoma
Related in Oncology
Sacubitril/Valsartan preserves left ventricular systolic function and attenuates GLS deterioration during chemotherapy
Sacubitril and Valsartan May Protect Heart Function During Chemotherapy
This meta-analysis of randomized controlled trials evaluates sacubitril/valsartan for patients undergoing chemotherapy to manage chemotherap…
A new review suggests the medication sacubitril/valsartan may help preserve heart muscle function for patients undergoing chemotherapy.
DaVinci Single-Port transoral robotic surgery is feasible across multiple indications including oncology and sleep apnea
Single-Port Robot Shows Promise for Sleep Apnea Surgery
This systematic review and meta-analysis of 479 patients evaluates the feasibility of DaVinci Single-Port (SP) transoral robotic surgery (TO…
A new analysis finds single-port robotic surgery for sleep apnea is feasible, with short operating times and low blood loss.
Neoadjuvant chemoimmunotherapy achieves higher pathological complete response rates than chemotherapy alone in muscle-invasive bladder cancer
Chemoimmunotherapy Shows Higher Response Rates in Bladder Cancer
This network meta-analysis of 2234 patients with muscle-invasive bladder cancer compares neoadjuvant chemoimmunotherapy (NICT), chemotherapy…
A new analysis shows that combining chemotherapy and immunotherapy may lead to higher response rates for patients with muscle-invasive bladd…
MRI Radiomics Predicts TERTp Mutation in Glioma with Moderate Accuracy
MRI Radiomics Help Predict TERTp Mutation in Glioma Patients
Meta-analysis of 14 studies shows MRI radiomics predicts TERTp mutation in glioma with AUC 0.79; combined models improve accuracy to 0.82.
New analysis shows MRI-based radiomics can help predict specific genetic mutations in glioma, potentially aiding early diagnosis and treatme…
From Other Specialties
Meningeal Immune System Offers New Target for Glioblastoma Immunotherapy
New approach targets the immune system to treat brain tumors
This systematic review explores how targeting the meningeal immune system, including dural lymphatics and rBAMs, could overcome current barr…
A new strategy focuses on the area where brain tumors meet the body's defenses to improve how immunotherapy works for glioblastoma.
A 6 dimension and 42 item system provides early risk assessment for high-risk diabetic feet
Experts Develop New Risk Assessment System for Diabetic Feet
This expert consultation and guideline describes the development of an early risk assessment system for high-risk diabetic feet. The consens…
A new assessment system identifies risk factors like nerve damage and circulation to help manage and prevent complications in patients with …
Rapid advancements in imaging and blood-based biomarkers are transforming the diagnosis and management of ADRD
New guidelines help doctors tell delirium from dementia
This clinical guideline provides a narrative review on the evolving diagnostic and treatment landscape for Alzheimer's disease and related d…
Delirium is acute and fluctuating; dementia is chronic. New guidelines help doctors tell them apart.
ACTH and vigabatrin achieved full seizure control in a patient with Ververi-Brady syndrome
ACTH and Vigabatrin Show Promise for Rare Epilepsy Syndrome
This case report describes a 5-month-old male infant with Ververi-Brady syndrome and infantile epileptic spasms syndrome. The patient achiev…
A new gene variant linked to Ververi-Brady syndrome showed positive results when treated with a combination of ACTH and vigabatrin.